有代表性的部分序列抽样报告
共166
其中从11月11日到上月24日，135
2019-12-26 1 1 坏事儿了，我的国！
2020-1-9 1 2 坏事儿呢，我的国
2020-1-22 2 4 坏大事呢，我的国
2020-3-25 1 5 坏事快要结，厉害啊，我的国！
2020-7-22 1 6 厉害了，我的国！
2020-9-24 1 7 厉害了，我的国！
2020-10-30 1 8 厉害了，我的国！
2020-12-17 1 9 厉害了，我的国！
2021-2-7 1 10 厉害了，我的国！
2021-3-18 1 11 厉害了，我的国！
2021-4-1 1 12 厉害了，我的国！
2021-4-3 1 13 厉害了，我的国！
2021-4-4 1 14 厉害了，我的国！
2021-5-29 1 15 厉害了，我的国！
2021-6-1 1 16 厉害了，我的国！
2021-6-6 1 17 厉害了，我的国！
2021-9-10 1 18 厉害了，我的国！
2021-9-16 1 19 厉害了，我的国！
2021-11-3 1 20 厉害了，我的国！
2022-1-24 1 21 厉害啊，大天津！
2022-2-26 1 22 厉害了，我的国！
2022-4-9 1 23 上海，你有病！
2022-4-10 1 24 上海，你有病！
2022-4-23 1 25 上海，你也病了太多的队友！
2022-5-5 2 27 上海，别的地方还抱怨呢
2022-5-12 1 28 上海，别的地方还抱怨呢
2022-7-1 1 29 稍微能歇点了，我的国唉
2022-11-3 2 31 还好吗，我的国？
2022-11-17 2 33 广州民工都运动过了！再看人家卡塔尔！ 2
2022-11-18 1 34 继续看人家卡塔尔，俺的国！ 3
2022-11-19 3 37 继续看人家卡塔尔，俺的国！ 6
2022-11-20 0 37 看不够的卡塔尔，俺的国！ 6
2022-11-21 0 37 看不够的卡塔尔，俺的国！ 6
2022-11-22 0 37 看不够的卡塔尔，俺的国！ 6
2022-11-23 5 42 看不够的卡塔尔，俺的国！ 11
2022-11-24 5 47 看不够的卡塔尔，俺的国！ 16
2022-11-25 2 49 看不够的卡塔尔，俺的国！ 18
2022-11-26 7 56 白纸运动吧，我的国！跟流感差不多 25
2022-11-27 7 63 白纸运动吧，我的国！跟流感差不多 32
2022-11-28 5 68 白纸运动吧，我的国！跟流感差不多 37
2022-11-29 3 71 白纸运动吧，我的国！跟流感差不多 40
2022-11-30 0 71 白纸运动吧，我的国！跟流感差不多 40
2022-12-1 6 77 “绝大多数无症状”即将到来 46
2022-12-2 5 82 “绝大多数无症状”即将到来 51
2022-12-3 0 82 “绝大多数无症状”即将到来 51
2022-12-4 7 89 “绝大多数无症状” 58
2022-12-5 5 94 “绝大多数无症状” 63
2022-12-6 4 98 “绝大多数无症状” 67
2022-12-7 2 100 “绝大多数无症状” 69
2022-12-8 3 103 “绝大多数无症状” 72
2022-12-9 8 111 “绝大多数无症状” 80
2022-12-10 4 115 “绝大多数无症状” 84
2022-12-11 0 115 “绝大多数无症状” 84
2022-12-12 3 118 “绝大多数无症状” 87
2022-12-13 4 122 “绝大多数无症状” 91
2022-12-14 5 127 “绝大多数无症状”愈演愈烈中 96
2022-12-15 5 132 “绝大多数无症状”愈演愈烈中 101
2022-12-16 1 133 “绝大多数无症状”愈演愈烈中 102
2022-12-17 5 138 “绝大多数无症状”愈演愈烈中 107
2022-12-18 1 139 “绝大多数无症状”愈演愈烈中 108
2022-12-19 5 144 “绝大多数无症状”愈演愈烈中 113
2022-12-20 4 148 “绝大多数无症状”愈演愈烈中 117
2022-12-21 6 154 “绝大多数无症状”愈演愈烈中 123
2022-12-22 8 162 “绝大多数无症状”愈演愈烈中 131
2022-12-23 0 162 “绝大多数无症状”愈演愈烈中 131
2022-12-24 4 166 “绝大多数无症状”愈演愈烈中 135
https://nextstrain.org/ncov/gisaid/asia ... egion=Asia
国产天然疫苗产量报告
版主： Softfist
Re: 国产天然疫苗产量报告
上面显示的只是有代表性的部分样品
中国的整体情况大致是：
Preliminary phylogenetic analyses continue to indicate that, when compared against the 14.4 million genomes in GISAID's EpiCov database, all closely resemble known globally circulating variants seen in different parts of the world between July and December. the analysis also revealed that the BF.7 outbreaks in Beijing and Fujian were potentially seeded from Inner Mongolia and there are ongoing BA.5.2 outbreaks in multiple cities. The new data from Shanghai show a range of additional known lineages from multiple separate introductions.
https://gisaid.org/
中国的整体情况大致是：
Preliminary phylogenetic analyses continue to indicate that, when compared against the 14.4 million genomes in GISAID's EpiCov database, all closely resemble known globally circulating variants seen in different parts of the world between July and December. the analysis also revealed that the BF.7 outbreaks in Beijing and Fujian were potentially seeded from Inner Mongolia and there are ongoing BA.5.2 outbreaks in multiple cities. The new data from Shanghai show a range of additional known lineages from multiple separate introductions.
https://gisaid.org/
上次由 meiyoumajia 在 2023年 1月 4日 17:20 修改。
Re: 国产天然疫苗产量报告
BF.7: 内蒙古和北京
BA.5.2: 广东、四川和重庆
二者兼得：福建、浙江和上海
上海另外还有BA.2.75和美国刚让位但仍占1/4以上的BQ.1.1
BA.5.2: 广东、四川和重庆
二者兼得：福建、浙江和上海
上海另外还有BA.2.75和美国刚让位但仍占1/4以上的BQ.1.1
上次由 meiyoumajia 在 2023年 1月 4日 14:40 修改。
Re: 国产天然疫苗产量报告
https://www.who.int/news/item/04-01-202 ... n-in-china
TAG-VE statement on the 3rd January meeting on the COVID-19 situation in China
4 January 2023 Statement Reading time: 2 min (488 words)
The Technical Advisory Group on Virus Evolution (TAG-VE) meets regularly to review the latest scientific evidence on circulating SARS-CoV-2 variants and advises WHO on whether a change in public health strategies are warranted. The TAG-VE met on 3 January 2023 to discuss the COVID-19 situation in mainland China.
During the meeting, scientists from China CDC presented genomic data from what they described as imported as well as locally-acquired cases of SARS-CoV-2 infections. For locally-acquired infections, data presented were based on more than 2000 genomes collected and sequenced from 1 December 2022. The China CDC analysis showed a predominance of Omicron lineages BA.5.2 and BF.7 among locally acquired infections. BA.5.2 and BF.7 together accounted for 97.5% of all local infections as per genomic sequencing. A few other known Omicron sublineages were also detected albeit in low percentages. These variants are known and have been circulating in other countries, and at the present time no new variant has been reported by the China CDC.
As of 3 January, 773 sequences from mainland China have been submitted to the GISAID EpiCoV database, with the majority (564 sequences) collected after 1 December 2022. Of those, only 95 are labeled as locally acquired cases, 187 as imported cases and 261 do not have this information provided. Of the locally acquired cases, 95% belong to BA.5.2 or BF.7 lineages. This is in line with genomes from travellers from China submitted to the GISAID EpiCoV database by other countries. No new variant or mutation of known significance is noted in the publicly available sequence data.
Acknowledging the information shared so far, the TAG-VE reiterates the critical need for and importance of additional analysis as well as sharing of sequence data to understand the evolution of SARS-CoV-2 and the emergence of concerning mutations or variants. This should be done regardless of whether a sequence is assigned a Pango lineage or not. This is best accomplished by rapid and regular depositing of data into publicly accessible databases. Maintaining high levels of representative genomic surveillance across China and globally, annotating genomic sequences with relevant clinical and epidemiological metadata, and rapid sharing of such data are the pillars of timely global risk assessment.
WHO will continue to closely monitor the situation in the People’s Republic of China and globally and urges all countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages, including on the severity of disease they cause. At this time, the TAG-VE is also evaluating the rapidly increasing proportion of XBB.1.5 in the United States and other countries. An updated risk-assessment of XBB.1.5, beyond the previous statement, is in progress.
The TAG-VE meets regularly and continues to assess the available data on the transmissibility, clinical severity, and immune escape potential of variants, including the potential impact on diagnostics, therapeutics, and the effectiveness of vaccines in preventing infection and/or severe disease.
TAG-VE statement on the 3rd January meeting on the COVID-19 situation in China
4 January 2023 Statement Reading time: 2 min (488 words)
The Technical Advisory Group on Virus Evolution (TAG-VE) meets regularly to review the latest scientific evidence on circulating SARS-CoV-2 variants and advises WHO on whether a change in public health strategies are warranted. The TAG-VE met on 3 January 2023 to discuss the COVID-19 situation in mainland China.
During the meeting, scientists from China CDC presented genomic data from what they described as imported as well as locally-acquired cases of SARS-CoV-2 infections. For locally-acquired infections, data presented were based on more than 2000 genomes collected and sequenced from 1 December 2022. The China CDC analysis showed a predominance of Omicron lineages BA.5.2 and BF.7 among locally acquired infections. BA.5.2 and BF.7 together accounted for 97.5% of all local infections as per genomic sequencing. A few other known Omicron sublineages were also detected albeit in low percentages. These variants are known and have been circulating in other countries, and at the present time no new variant has been reported by the China CDC.
As of 3 January, 773 sequences from mainland China have been submitted to the GISAID EpiCoV database, with the majority (564 sequences) collected after 1 December 2022. Of those, only 95 are labeled as locally acquired cases, 187 as imported cases and 261 do not have this information provided. Of the locally acquired cases, 95% belong to BA.5.2 or BF.7 lineages. This is in line with genomes from travellers from China submitted to the GISAID EpiCoV database by other countries. No new variant or mutation of known significance is noted in the publicly available sequence data.
Acknowledging the information shared so far, the TAG-VE reiterates the critical need for and importance of additional analysis as well as sharing of sequence data to understand the evolution of SARS-CoV-2 and the emergence of concerning mutations or variants. This should be done regardless of whether a sequence is assigned a Pango lineage or not. This is best accomplished by rapid and regular depositing of data into publicly accessible databases. Maintaining high levels of representative genomic surveillance across China and globally, annotating genomic sequences with relevant clinical and epidemiological metadata, and rapid sharing of such data are the pillars of timely global risk assessment.
WHO will continue to closely monitor the situation in the People’s Republic of China and globally and urges all countries to continue to be vigilant, to monitor and report sequences, as well as to conduct independent and comparative analyses of the different Omicron sublineages, including on the severity of disease they cause. At this time, the TAG-VE is also evaluating the rapidly increasing proportion of XBB.1.5 in the United States and other countries. An updated risk-assessment of XBB.1.5, beyond the previous statement, is in progress.
The TAG-VE meets regularly and continues to assess the available data on the transmissibility, clinical severity, and immune escape potential of variants, including the potential impact on diagnostics, therapeutics, and the effectiveness of vaccines in preventing infection and/or severe disease.
Re: 国产天然疫苗产量报告
南方整体要小心BF.7的继续大扩散。能明显传到上海、浙江和福建，就也会到其它地方。
另外还会有BQ.1.1,在美国和日本都大量流行的病株。中国才正要第一次完成群面，还不知道会不会对这种较新或者比较陌生的病株敏感。
大部分农村还早着呢。现在很多在外工作的人在往家乡赶。
死亡高峰期可能还没到。后遗症者至少会有几百万，其中不小比例可能会是比较年轻的人。
南北病毒株才开始交流。而且会有新的变异株被引进。
再过2至3个月整体情况才会清楚。
迟早会自产一些新变种。难以保证全都没什么害。
另外还会有BQ.1.1,在美国和日本都大量流行的病株。中国才正要第一次完成群面，还不知道会不会对这种较新或者比较陌生的病株敏感。
大部分农村还早着呢。现在很多在外工作的人在往家乡赶。
死亡高峰期可能还没到。后遗症者至少会有几百万，其中不小比例可能会是比较年轻的人。
南北病毒株才开始交流。而且会有新的变异株被引进。
再过2至3个月整体情况才会清楚。
迟早会自产一些新变种。难以保证全都没什么害。
Re: 国产天然疫苗产量报告
北京也有了不少广州和其它南方地区最多的那种
BF.7 (55)
BA.5.2 (11)
BA.5.2.1 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
BF.7 (55)
BA.5.2 (11)
BA.5.2.1 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
Re: 国产天然疫苗产量报告
南北一直在交流吧？meiyoumajia 写了： 2023年 1月 4日 14:31 南方整体要小心BF.7的继续大扩散。能明显传到上海、浙江和福建，就也会到其它地方。
另外还会有BQ.1.1,在美国和日本都大量流行的病株。中国才正要第一次完成群面，还不知道会不会对这种较新或者比较陌生的病株敏感。
大部分农村还早着呢。现在很多在外工作的人在往家乡赶。
死亡高峰期可能还没到。后遗症者至少会有几百万，其中不小比例可能会是比较年轻的人。
南北病毒株才开始交流。而且会有新的变异株被引进。
再过2至3个月整体情况才会清楚。
迟早会自产一些新变种。难以保证全都没什么害。
Re: 国产天然疫苗产量报告
台湾
类似万花筒，”优先地“全面/“美化/日化/国际化”程度更高
BA.5.1 (3)
BA.5.2 (2)
BA.5.2.1 (2)
BA.5.2.27 (2)
BA.5.2.34 (2)
BE.1.1 (2)
BF.27 (1)
BN.1.3 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
类似万花筒，”优先地“全面/“美化/日化/国际化”程度更高
BA.5.1 (3)
BA.5.2 (2)
BA.5.2.1 (2)
BA.5.2.27 (2)
BA.5.2.34 (2)
BE.1.1 (2)
BF.27 (1)
BN.1.3 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
Re: 国产天然疫苗产量报告
所以和南北交流没关系meiyoumajia 写了： 2023年 1月 4日 16:47 我从来没说是新变种。变得严重了/或者有了比较大大突变后才能被认为是新变种。
要产生新变种需要较长时间。中国大陆可能还要好几周才会有明显的产生。
Re: 国产天然疫苗产量报告
上海
中国承受病毒变种入侵压力最大的一个城市（与广州差不多？北京什么都差远了）
美国有的，上海也都不少。BQ.1,BQ.1.1和XBB是美国的三大。
BA.5.2 (49)
BQ.1.1 (35)
BF.7 (23)
BQ.1 (17)
BA.5 (14)
BA.5.2.1 (13)
XBB.1 (11)
BA.5.2.6 (5)
BN.1.3.1 (5)
BF.7.12 (4)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
中国承受病毒变种入侵压力最大的一个城市（与广州差不多？北京什么都差远了）
美国有的，上海也都不少。BQ.1,BQ.1.1和XBB是美国的三大。
BA.5.2 (49)
BQ.1.1 (35)
BF.7 (23)
BQ.1 (17)
BA.5 (14)
BA.5.2.1 (13)
XBB.1 (11)
BA.5.2.6 (5)
BN.1.3.1 (5)
BF.7.12 (4)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
上次由 meiyoumajia 在 2023年 1月 4日 16:58 修改。
Re: 国产天然疫苗产量报告
当然有很大关系了。病毒当然是尽量就近传播。从人口交流/运输上看，上海差不多是南北兼具的一个最大点。
上海可以辐射南方沿海。广州可以辐射周边。但北京和广州的直接交流就会比北京与上海差了不少。因此，多少还是有个明显的南北界限，尽管现在的交通很发达。到广东打工的显然南方人比例大得多。
Re: 国产天然疫苗产量报告
江苏
有点小小地沾上海的光？
BN.1.3 (4)
BF.5 (2)
BF.7 (2)
BA.5.2 (1)
BN.1.1.1 (1)
BQ.1.1 (1)
BQ.1.1.13 (1)
BQ.1.2 (1)
XBB.1 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01
有点小小地沾上海的光？
BN.1.3 (4)
BF.5 (2)
BF.7 (2)
BA.5.2 (1)
BN.1.1.1 (1)
BQ.1.1 (1)
BQ.1.1.13 (1)
BQ.1.2 (1)
XBB.1 (1)
https://ngdc.cncb.ac.cn/ncov/genome/sea ... 2022-12-01